Drug Profile
Enoblituzumab - MacroGenics
Alternative Names: Anti-B7-H3 mAb; MGA-271; TJ 271Latest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator MacroGenics
- Developer I-MAB Biopharma; MacroGenics; Masonic Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD276 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
- Discontinued Bladder cancer; Fallopian tube cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
Most Recent Events
- 15 Apr 2024 I-MAb Biopharma withdraws the phase II Basket trial in Solid tumours (Late-stage disease, Combination therapy) in China (Injection), due to company development strategy adjustment (NCT05338580)
- 04 Apr 2024 Discontinued - Phase-I for Fallopian tube cancer (Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV) as of April 2024 (MacroGenics pipeline, April 2024)
- 04 Apr 2024 Discontinued - Phase-I for Malignant melanoma (Combination therapy, Inoperable/Unresectable, Locally recurrent, Metastatic disease, Second-line therapy or greater) in USA (IV) as of April 2024 (MacroGenics pipeline, April 2024)